Skip to main content
Venus Remedies Ltd. logo

Venus Remedies Ltd. — Investor Relations & Filings

Ticker · VENUSREM ISIN · INE411B01019 LEI · 335800PBHMB6GQMFN127 BSE.NS Manufacturing
Open in API
Filings indexed 620 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country IN India
Listing BSE.NS VENUSREM

About Venus Remedies Ltd.

https://venusremedies.com/

Venus Remedies Ltd. is a research-driven organization specializing in the development and manufacturing of innovative pharmaceutical formulations. The company focuses on critical therapeutic segments, including antimicrobial resistance, oncology, neurology, orthopedics, and pain management. It operates advanced manufacturing facilities and maintains a dedicated research and development wing, the Venus Medicine Research Centre, which prioritizes the creation of novel drug delivery systems and solutions for multi-drug resistant infections. Its product portfolio features a diverse range of injectables and specialized treatments, such as Elores, aimed at addressing complex clinical needs. The company serves a global market, providing healthcare solutions through a commitment to scientific excellence and international regulatory standards.

Recent filings

Filing Released Lang Actions
As per file enclosed
Regulatory Filings Classification · 85% confidence The document is a regulatory disclosure of the Board Meeting outcomes under SEBI Listing Regulations (Regulation 30 and 33). It includes approval of audited financial results for Q4 and FY‐ended March 31, 2026, scheduling of the AGM, dividend record date, appointments and reappointments of directors and auditors, adoption of new MOA/AOA, trading window closure, and an annexed Independent Auditor’s Report. It is not the full Annual Report or standalone financial statements with MD&A, nor a simple PR of results, but rather a broad compliance filing notifying the stock exchanges of material board decisions. This fits the ‘Regulatory Filings’ (RNS) category as a general SEBI compliance announcement.
2026-05-26 English
Outcome of Board Meeting
Regulatory Filings Classification · 85% confidence The document is an exchange filing under SEBI Listing Regulations detailing the outcome of a Board Meeting held on 26 May 2026. It: 1. Announces approval of audited financial results (with the detailed results annexed rather than embedded). 2. Schedules the Annual General Meeting and sets a record date for dividend. 3. Recommends dividend and auditor appointments. 4. Announces multiple director appointments/reappointments, adoption of new MOA/AOA, and trading window closure. Although it references financial results and includes an Independent Auditor’s Report, the body of the text is a composite regulatory compliance notice (Regulation 30/33 intimation) rather than the full financial statements or management commentary. It is not simply a stand-alone financial or interim report (IR/10-K) nor a narrow earnings release (ER), nor solely a management change notice (MANG). It is best classified under the general regulatory announcements category.
2026-05-26 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 89% confidence The document is the official outcome of the Board Meeting sent to the stock exchanges under SEBI LODR, containing the Audited Financial Results for the quarter and year ended March 31, 2026, along with the Statutory Auditor’s report. It is not a full Annual Report (10-K) nor just an earnings highlights release. Instead, it provides substantive financial statements and audit opinions for a period shorter than a full fiscal year (quarter and year‐end results) in a regulatory filing format. This matches the definition of an Interim/Quarterly Report (IR). FY 2026
2026-05-26 English
As the file enclosed.
Regulatory Filings Classification · 85% confidence The document is an ‘Outcome of Board Meeting’ filing under SEBI Listing Regulations, summarizing multiple items approved by the Board: audited standalone and consolidated financial results, auditor’s report, date of the AGM, dividend proposal, director and auditor appointments, adoption of new MOA/AOA, and trading window closure. It is a composite regulatory compliance announcement rather than the full Annual or Interim Report itself, a pure audit opinion, or a stand-alone management discussion. It aligns with general regulatory filings (fallback category) for corporate disclosures under Listing Obligations.
2026-05-26 English
Updates
Regulatory Filings Classification · 75% confidence The document is an intimation under Regulation 30 of the SEBI LODR regulations, submitting a press release to stock exchanges about a marketing authorization approval. It is a regulatory disclosure announcement with no financial statements or substantive report content. This falls under general regulatory/compliance filings rather than a financial report or other specific categories. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-22 English
As per the pdf enclosed
Regulatory Filings Classification · 87% confidence The document is a press release filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notifying the exchange of a corporate development (Saudi FDA approval). It contains no financial statements or data, and is a routine regulatory/intelligence announcement. This fits the “Regulatory Filings” category as a general announcement (RNS), not a financial report or ESG disclosure.
2026-05-22 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.